RPG Life Sciences Limited
NSE: RPGLIFE BSE: RPGLIFE
Prev Close
2431.1
Open Price
2394.6
Volume
6,281
Today Low / High
2392 / 2451.9
52 WK Low / High
1835 / 2744.8
Range
2,284 - 2,524
Prev Close
2436.45
Open Price
2411.05
Volume
259
Today Low / High
2392 / 2452.75
52 WK Low / High
1772.05 / 2775.65
Range
2,287 - 2,528
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 2403.9 (target range: 2,284 - 2,524), reflecting a change of -27.2 (-1.11884%). On the BSE, it is listed at 2407.15 (target range: 2,287 - 2,528), showing a change of -29.3 (-1.20257%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
RPG Life Sciences Limited Graph
RPG Life Sciences Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for RPG Life Sciences Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 2,403.90, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range | 
|---|---|---|---|
| Bullish Scenario | 2,407.15 | 2,431.22 | 2,188.10 - 2,674.34 | 
| 2,455.29 | 1,964.23 - 2,946.35 | ||
| 2,479.36 | 1,735.56 - 3,223.17 | ||
| Bearish Scenario | 2,407.15 | 2,383.08 | 2,144.77 - 2,621.39 | 
| 2,359.01 | 1,887.21 - 2,830.81 | ||
| 2,334.94 | 1,634.45 - 3,035.42 | 
Overview of RPG Life Sciences Limited
ISIN
INE105J01010
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
12,920
Market Cap
40,221,230,579
Last Dividend
20
Official Website
IPO Date
2002-08-12
DCF Diff
-4,161.83
DCF
6,513
Financial Ratios Every Investor Needs
Stock Dividend of RPGLIFE
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date | 
|---|---|---|---|---|---|---|
| 2025-06-27 | June 27, 25 | 20 | 20 | 2025-06-27 | 2025-08-15 | |
| 2024-06-28 | June 28, 24 | 16 | 16 | 2024-06-28 | 2024-08-15 | |
| 2023-07-21 | July 21, 23 | 12 | 12 | 2023-07-21 | 2023-09-03 | |
| 2022-07-14 | July 14, 22 | 9.6 | 9.6 | 2022-07-15 | 2022-08-28 | |
| 2021-08-13 | August 13, 21 | 7.2 | 7.2 | 2021-08-17 | 2021-09-30 | 
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR | 
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 653.43 Cr | 214.01 Cr | 439.42 Cr | 0.6725 | 1.47 Cr | 127.21 Cr | 313.28 Cr | 183.24 Cr | 110.80 | 159.65 Cr | 0.2804 | 
| 2024-03-31 | 577.48 Cr | 371.29 Cr | 392.78 Cr | 0.6802 | 9.36 Cr | 132.89 Cr | 109.99 Cr | 87.66 Cr | 53.00 | 136.35 Cr | 0.1518 | 
| 2023-03-31 | 509.08 Cr | 340.59 Cr | 169.69 Cr | 0.3333 | 8.93 Cr | 117.75 Cr | 87.47 Cr | 67.64 Cr | 40.90 | 108.33 Cr | 0.1329 | 
| 2022-03-31 | 437.16 Cr | 150.21 Cr | 286.95 Cr | 0.6564 | 8.97 Cr | 100.63 Cr | 70.74 Cr | 51.48 Cr | 31.13 | 90.24 Cr | 0.1178 | 
| 2021-03-31 | 383.40 Cr | 137.64 Cr | 245.76 Cr | 0.6410 | 8.88 Cr | 95.36 Cr | 54.72 Cr | 40.00 Cr | 24.19 | 71.84 Cr | 0.1043 | 
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. | 
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 28.70 Cr | 657.81 Cr | 127.28 Cr | 530.5300 Cr | 0.00 Cr | -139.61 Cr | 92.98 Cr | 165.13 Cr | 0.00 Cr | 0.00 Cr | 1.18 Cr | 119.8300 Cr | 
| 2024-03-31 | 19.72 Cr | 512.87 Cr | 138.02 Cr | 374.8500 Cr | 0.00 Cr | -19.72 Cr | 101.00 Cr | 181.81 Cr | 1.84 Cr | 0.00 Cr | 1.20 Cr | 130.9600 Cr | 
| 2023-03-31 | 24.82 Cr | 419.35 Cr | 111.75 Cr | 307.6000 Cr | 0.01 Cr | -24.81 Cr | 95.05 Cr | 116.30 Cr | 31.88 Cr | 3.02 Cr | 0.18 Cr | 102.7800 Cr | 
| 2022-03-31 | 56.94 Cr | 344.61 Cr | 88.84 Cr | 255.7700 Cr | 0.94 Cr | -56.00 Cr | 82.99 Cr | 100.09 Cr | 2.46 Cr | 3.13 Cr | -12.48 Cr | 80.1100 Cr | 
| 2021-03-31 | 40.36 Cr | 303.39 Cr | 86.94 Cr | 216.4500 Cr | 2.02 Cr | -38.34 Cr | 58.33 Cr | 87.94 Cr | 24.53 Cr | 0.00 Cr | -1.25 Cr | 79.6900 Cr | 
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory | 
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 77.8600 Cr | -41.8000 Cr | -27.0800 Cr | 41.8300 Cr | 8.9800 Cr | 28.7000 Cr | -36.0300 Cr | 183.2400 Cr | 0.0000 Cr | -26.4600 Cr | 6.1900 Cr | 
| 2024-03-31 | 94.3600 Cr | -79.1500 Cr | -20.3100 Cr | 25.1300 Cr | -5.1000 Cr | 19.7200 Cr | -69.2300 Cr | 87.6600 Cr | -0.0100 Cr | -19.8500 Cr | -5.9500 Cr | 
| 2023-03-31 | 90.8200 Cr | -105.8100 Cr | -17.1200 Cr | 58.0900 Cr | -32.1200 Cr | 24.8200 Cr | -32.7300 Cr | 91.6800 Cr | -0.2800 Cr | -15.8800 Cr | -12.0600 Cr | 
| 2022-03-31 | 64.7500 Cr | -34.6600 Cr | -13.5100 Cr | 40.8000 Cr | 16.5800 Cr | 56.9400 Cr | -23.9500 Cr | 73.1700 Cr | -0.4200 Cr | -11.9100 Cr | -24.6600 Cr | 
| 2021-03-31 | 58.2700 Cr | -7.9600 Cr | -10.4900 Cr | 49.7600 Cr | 39.8200 Cr | 40.3600 Cr | -8.5100 Cr | 53.5800 Cr | -9.0700 Cr | 0.0000 Cr | -11.7200 Cr | 
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR | 
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 168.92 Cr | 60.02 Cr | 108.90 Cr | 0.6447 | 30.33 Cr | 26.29 Cr | 15.90 | 40.70 Cr | 0.1556 | 
| 2025-03-31 | 143.09 Cr | 48.72 Cr | 94.37 Cr | 0.6595 | 62.77 Cr | 117.35 Cr | 70.96 | 25.48 Cr | 0.8201 | 
| 2024-12-31 | 172.71 Cr | 56.11 Cr | 116.60 Cr | 0.6751 | 43.70 Cr | 34.93 Cr | 21.12 | 52.47 Cr | 0.2022 | 
| 2024-09-30 | 172.21 Cr | 54.17 Cr | 118.04 Cr | 0.6854 | 40.62 Cr | 4.20 Cr | 2.54 | 20.57 Cr | 0.0244 | 
| 2024-06-30 | 165.42 Cr | 93.04 Cr | 72.38 Cr | 0.4376 | 33.78 Cr | 26.76 Cr | 16.18 | 41.44 Cr | 0.1618 | 
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities | 
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 264.60 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -530.53 Cr | 
| 2025-03-31 | 28.70 Cr | 235.90 Cr | 265.51 Cr | 86.76 Cr | 92.98 Cr | 465.25 Cr | 165.13 Cr | 657.81 Cr | 127.28 Cr | 
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 125.94 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -379.38 Cr | 
| 2024-09-30 | 34.03 Cr | 91.91 Cr | 125.94 Cr | 86.41 Cr | 99.16 Cr | 330.17 Cr | 181.79 Cr | 554.37 Cr | 174.99 Cr | 
| 2024-06-30 | -125.87 Cr | 251.74 Cr | 125.87 Cr | 0.00 Cr | 0.00 Cr | 125.87 Cr | 0.00 Cr | 0.00 Cr | -374.85 Cr | 
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow | 
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 26.29 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 
| 2025-03-31 | 117.35 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 
| 2024-12-31 | 34.93 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 
| 2024-09-30 | 4.20 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 
| 2024-06-30 | 26.76 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 
Splits History
| Date | Label | Split Ratio | 
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume | 
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,690.70 | ₹4,056,549,508,373.00 | ₹1,560,907.00 | 
| Divi's Laboratories Limited | DIVISLAB | ₹6,738.00 | ₹1,788,732,898,056.00 | ₹507,645.00 | 
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,560.10 | ₹1,204,898,044,500.00 | ₹354,021.00 | 
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,197.60 | ₹996,839,216,220.00 | ₹4,250,056.00 | 
| Mankind Pharma Limited | MANKIND | ₹2,384.00 | ₹984,016,240,160.00 | ₹593,366.00 | 
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹974.45 | ₹980,520,395,716.00 | ₹458,971.00 | 
| Lupin Limited | LUPIN | ₹1,963.50 | ₹896,844,333,000.00 | ₹1,017,447.00 | 
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,138.90 | ₹661,474,968,435.00 | ₹3,556,831.00 | 
| Alkem Laboratories Limited | ALKEM | ₹5,506.50 | ₹658,384,672,500.00 | ₹178,327.00 | 
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,891.20 | ₹533,698,169,981.00 | ₹398,054.00 | 
| Laurus Labs Limited | LAURUSLABS | ₹953.65 | ₹514,804,014,931.00 | ₹1,545,364.00 | 
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 | 
| Ipca Laboratories Limited | IPCALAB | ₹1,271.20 | ₹322,508,801,922.00 | ₹106,442.00 | 
| Ajanta Pharma Limited | AJANTPHARM | ₹2,465.30 | ₹308,003,793,847.00 | ₹102,941.00 | 
| Cohance Lifesciences Limited | COHANCE | ₹753.40 | ₹288,226,083,276.00 | ₹1,868,840.00 | 
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,682.30 | ₹263,441,852,870.00 | ₹161,890.00 | 
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 | 
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,318.90 | ₹250,017,076,708.00 | ₹201,166.00 | 
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,555.00 | ₹238,875,000,000.00 | ₹20,033.00 | 
| Eris Lifesciences Limited | ERIS | ₹1,591.70 | ₹216,811,113,902.00 | ₹40,393.00 | 
| Neuland Laboratories Limited | NEULANDLAB | ₹16,473.00 | ₹211,346,761,497.00 | ₹44,604.00 | 
| Wockhardt Limited | WOCKPHARMA | ₹1,281.50 | ₹208,224,272,482.00 | ₹289,135.00 | 
| Alembic Pharmaceuticals Limited | APLLTD | ₹897.40 | ₹176,395,747,478.00 | ₹69,233.00 | 
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,101.00 | ₹174,564,413,184.00 | ₹543,954.00 | 
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,032.80 | ₹154,516,575,629.00 | ₹43,860.00 | 
| NATCO Pharma Limited | NATCOPHARM | ₹819.90 | ₹146,852,182,413.00 | ₹412,467.00 | 
| Granules India Limited | GRANULES | ₹565.60 | ₹137,253,425,770.00 | ₹384,397.00 | 
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 | 
| Alivus Life Sciences Ltd. | ALIVUS | ₹904.45 | ₹110,959,145,199.00 | ₹27,710.00 | 
| Procter & Gamble Health Limited | PGHL | ₹6,152.00 | ₹102,119,398,064.00 | ₹17,413.00 | 
| Strides Pharma Science Limited | STAR | ₹934.70 | ₹86,153,835,776.00 | ₹9,219,602.00 | 
| Aarti Pharmalabs Limited | AARTIPHARM | ₹851.95 | ₹77,214,757,940.00 | ₹105,286.00 | 
| FDC Limited | FDC | ₹460.65 | ₹74,998,465,195.00 | ₹252,540.00 | 
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹460.75 | ₹70,541,773,224.00 | ₹53,334.00 | 
| Shilpa Medicare Limited | SHILPAMED | ₹352.85 | ₹69,011,043,776.00 | ₹149,611.00 | 
| Sequent Scientific Limited | SEQUENT | ₹214.61 | ₹53,633,796,524.00 | ₹1,034,635.00 | 
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹465.10 | ₹50,679,744,752.00 | ₹51,856.00 | 
| Innova Captab Limited | INNOVACAP | ₹831.10 | ₹47,559,638,492.00 | ₹13,222.00 | 
| Aarti Drugs Limited | AARTIDRUGS | ₹491.10 | ₹44,822,697,000.00 | ₹54,690.00 | 
| Sun Pharma Advanced Research Company Limited | SPARC | ₹135.19 | ₹43,872,073,482.00 | ₹196,488.00 | 
| Suven Life Sciences Limited | SUVEN | ₹197.55 | ₹43,073,939,692.00 | ₹121,404.00 | 
| RPG Life Sciences Limited | RPGLIFE | ₹2,403.90 | ₹39,758,138,159.00 | ₹6,281.00 | 
| Orchid Pharma Limited | ORCHPHARMA | ₹726.30 | ₹36,837,285,962.00 | ₹86,074.00 | 
| Unichem Laboratories Limited | UNICHEMLAB | ₹470.95 | ₹33,157,587,963.00 | ₹3,282.00 | 
| Gufic Biosciences Limited | GUFICBIO | ₹325.40 | ₹32,631,927,452.00 | ₹54,623.00 | 
Key Executives
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: female
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
FAQs about RPG Life Sciences Limited
The CEO is Ashok Nair.
The current price is ₹2,431.90.
The range is ₹1835-2744.8.
The market capitalization is ₹4,022.12 crores.
The dividend yield is 0.82%.
The P/E ratio is 22.00.
The company operates in the Healthcare sector.
Overview of RPG Life Sciences Limited (ISIN: INE105J01010) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹4,022.12 crores and an average daily volume of 12,920 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹20.
